当归(当归)会增加乳腺癌风险吗?系统回顾

Ying-Ling Chen, M. C. Hou, Y. Hsu
{"title":"当归(当归)会增加乳腺癌风险吗?系统回顾","authors":"Ying-Ling Chen, M. C. Hou, Y. Hsu","doi":"10.14218/fim.2023.00002","DOIUrl":null,"url":null,"abstract":"Background and objecties: Angelica sinensis (Dang gui) has been widely used in traditional Chinese medicine (TCM) clinics and diet therapy for thousands of years. According to TCM theory, A. sinensis can be used for the treatment of breast cancer. As A. sinensis has effects on estrogen, it may have an adverse effect on the prognosis of breast cancer. This article systematically reviews the literature to explore whether breast cancer patients need to avoid taking A. sinensis . Methods: Using the search terms “breast cancer AND Dong-quai”, “breast cancer AND Angelica sinensis ”, “breast cancer AND Dang gui” and “breast cancer AND Dang qui”, relevant studies were retrieved from the PubMed database up to December 31, 2022. After excluding irrelevant and repeated studies, the papers were critically reviewed by TCM physicians, and the papers were secondly screened by the impact factor and ranking of the published journals. The included papers were classified into three groups, reporting a “positive”, “negative” or “inconclusive” effect in patients with breast cancer. Results: A total of 22 articles were identified, which included 9, 5 and 7 positive negative and inconclusive studies, respectively. The results showed that studies advocating that A. sinensis may be safely consumed by patients with breast cancer had a higher evidence hierarchy than those that did not support consumption. Conclusions: The findings implied that A. sinensis can be prescribed to patients with breast cancer in appropriate doses under TCM treatment theory.","PeriodicalId":73126,"journal":{"name":"Future integrative medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Does Angelica Sinensis (Dang-qui) Increase the Risk of Breast Cancer? A Systematic Review\",\"authors\":\"Ying-Ling Chen, M. C. Hou, Y. Hsu\",\"doi\":\"10.14218/fim.2023.00002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and objecties: Angelica sinensis (Dang gui) has been widely used in traditional Chinese medicine (TCM) clinics and diet therapy for thousands of years. According to TCM theory, A. sinensis can be used for the treatment of breast cancer. As A. sinensis has effects on estrogen, it may have an adverse effect on the prognosis of breast cancer. This article systematically reviews the literature to explore whether breast cancer patients need to avoid taking A. sinensis . Methods: Using the search terms “breast cancer AND Dong-quai”, “breast cancer AND Angelica sinensis ”, “breast cancer AND Dang gui” and “breast cancer AND Dang qui”, relevant studies were retrieved from the PubMed database up to December 31, 2022. After excluding irrelevant and repeated studies, the papers were critically reviewed by TCM physicians, and the papers were secondly screened by the impact factor and ranking of the published journals. The included papers were classified into three groups, reporting a “positive”, “negative” or “inconclusive” effect in patients with breast cancer. Results: A total of 22 articles were identified, which included 9, 5 and 7 positive negative and inconclusive studies, respectively. The results showed that studies advocating that A. sinensis may be safely consumed by patients with breast cancer had a higher evidence hierarchy than those that did not support consumption. Conclusions: The findings implied that A. sinensis can be prescribed to patients with breast cancer in appropriate doses under TCM treatment theory.\",\"PeriodicalId\":73126,\"journal\":{\"name\":\"Future integrative medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future integrative medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14218/fim.2023.00002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14218/fim.2023.00002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景与目的:当归被广泛应用于中医临床和食疗已有上千年的历史。根据中医理论,中华沙棘可用于治疗乳腺癌。由于中华沙棘对雌激素有影响,可能对乳腺癌的预后有不良影响。本文系统回顾文献,探讨乳腺癌患者是否需要避免服用中华乳杆菌。方法:使用检索词“乳腺癌与东桂”、“乳腺癌与当归”、“乳腺癌与党桂”和“乳腺癌与党桂”,从PubMed数据库中检索截至2022年12月31日的相关研究。在排除不相关和重复研究后,由中医医师对论文进行批判性评议,并通过发表期刊的影响因子和排名对论文进行二次筛选。纳入的论文被分为三组,分别报道了对乳腺癌患者的“积极”、“消极”或“不确定”的影响。结果:共纳入22篇文献,其中阳性、阴性和不确定研究分别为9篇、5篇和7篇。结果表明,主张乳腺癌患者可以安全食用中华按蚊的研究比不支持食用的研究具有更高的证据层次。结论:在中医治疗理论的指导下,中华沙棘可在适当剂量下用于乳腺癌患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Does Angelica Sinensis (Dang-qui) Increase the Risk of Breast Cancer? A Systematic Review
Background and objecties: Angelica sinensis (Dang gui) has been widely used in traditional Chinese medicine (TCM) clinics and diet therapy for thousands of years. According to TCM theory, A. sinensis can be used for the treatment of breast cancer. As A. sinensis has effects on estrogen, it may have an adverse effect on the prognosis of breast cancer. This article systematically reviews the literature to explore whether breast cancer patients need to avoid taking A. sinensis . Methods: Using the search terms “breast cancer AND Dong-quai”, “breast cancer AND Angelica sinensis ”, “breast cancer AND Dang gui” and “breast cancer AND Dang qui”, relevant studies were retrieved from the PubMed database up to December 31, 2022. After excluding irrelevant and repeated studies, the papers were critically reviewed by TCM physicians, and the papers were secondly screened by the impact factor and ranking of the published journals. The included papers were classified into three groups, reporting a “positive”, “negative” or “inconclusive” effect in patients with breast cancer. Results: A total of 22 articles were identified, which included 9, 5 and 7 positive negative and inconclusive studies, respectively. The results showed that studies advocating that A. sinensis may be safely consumed by patients with breast cancer had a higher evidence hierarchy than those that did not support consumption. Conclusions: The findings implied that A. sinensis can be prescribed to patients with breast cancer in appropriate doses under TCM treatment theory.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Exploring the Molecular Mechanisms and Therapeutic Potentials of Essential Oils: A Systems Biology Approach Magnetic Resonance Study on Restoration of the Glymphatic System and Brain Network in Insomnia Patients with TCM Physiotherapy: A Case Report Meta-analysis of the Correlation between Traditional Chinese Medicine Syndrome of Lung Cancer and Tumor-node-metastasis Staging Indexes Exploring the Safety, Efficacy, and Bioactivity of Herbal Medicines: Bridging Traditional Wisdom and Modern Science in Healthcare Coptis teeta Wall.: A Comprehensive Overview of its Traditional Uses, Pharmacological Uses, Phytochemicals and Conservation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1